Cost-effectiveness of fluticasone propionate/salmeterol (500/50 μg) in the treatment of COPD - 08/08/11
, Michele R. Wilson a, Anand A. Dalal b, Mike G. Chambers b, Priti Jhingran b, Richard Stanford b, Douglas W. Mapel c
Correspondence to: Stephanie R. Earnshaw, 200 Park Offices Drive, PO Box 12194, Research Triangle Park, NC 27709, USA. Tel.: +1 919 485 2730; fax: +1 919 541 7222.Summary |
Objective |
We examine the lifetime cost-effectiveness of treatment with fluticasone propionate/salmeterol (500/50μg) compared with no maintenance treatment in COPD in the US.
Methods |
A decision-analytic model was developed to estimate lifetime costs and outcomes associated with fluticasone propionate/salmeterol 500/50 μg treatment, salmeterol 50μg, and fluticasone propionate 500μg compared to no maintenance treatment in treating COPD from a third-party US payer perspective. The patient population was similar to that of the TORCH clinical trial. Model structure and inputs were obtained from published literature and clinical trial data. All costs are presented in 2006 US dollars. Outcomes included cost per life year (LY) saved and cost per quality-adjusted life year (QALY) gained. Costs and outcomes were discounted at 3% annually. Univariate and multivariate sensitivity analyses were conducted to assess model robustness.
Results |
Compared to no maintenance treatment, treatment with fluticasone propionate/salmeterol 500/50μg results in a lifetime incremental cost-effectiveness ratio (ICER) of $33,865/QALY. Treatment with salmeterol 50μg was found to have an ICER of $20,797/QALY. These results are robust to changes in input parameters. Fluticasone propionate 500μg was dominated by no treatment, though the results were not robust to changes in parameters.
Conclusions |
Treatment of COPD with fluticasone propionate/salmeterol 500/50μg appears to be cost-effective (≤$50,000/QALY) compared to no maintenance treatment. Similarly, salmeterol 50μg may be cost-effective compared to no maintenance treatment. Compared with no maintenance treatment, fluticasone propionate 500μg was effective in reducing number of exacerbations, but failure to differentiate from no maintenance treatment in mortality resulted in it being dominated in the base case.
Le texte complet de cet article est disponible en PDF.Key words : COPD, Cost-effectiveness analysis, Economics
Plan
Vol 103 - N° 1
P. 12-21 - janvier 2009 Retour au numéro
Article précédent
- 50 Years of psychological research on patients with COPD – Road to ruin or highway to heaven?
- Ad A. Kaptein, Margreet Scharloo, Maarten J. Fischer, Lucia Snoei, Brian M. Hughes, John Weinman, Robert M. Kaplan, Klaus F. Rabe
- The efficacy of tiotropium administered via Respimat® Soft Mist™ Inhaler or HandiHaler® in COPD patients
- J.A. van Noord, P.J.G. Cornelissen, J.-L. Aumann, J. Platz, A. Mueller, C. Fogarty
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?